Abeona Therapeutics Announces Upcoming Presentations
May 08, 2018 08:15 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, May 08, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical- stage biopharmaceutical company focused on developing novel cell and gene...
Abeona Announces FDA Grants RMAT Designation to ABO-102 Gene Therapy in MPS IIIA
April 23, 2018 08:15 ET
|
Abeona Therapeutics Inc.
First Gene Therapy Using AAV Approach Granted Regenerative Medicine Advanced Therapy Designation NEW YORK and CLEVELAND, April 23, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics...
Abeona Therapeutics Receives Orphan Drug Designation in the European Union for ABO-202 Gene Therapy Program in Batten Disease
April 20, 2018 08:15 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, April 20, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and...
Abeona Therapeutics Appoints Carsten Thiel, Ph.D., as Chief Executive Officer
April 02, 2018 08:15 ET
|
Abeona Therapeutics Inc.
Company strengthens management team with biopharmaceutical veteran bringing extensive commercial experience in life-threatening rare diseases Tim Miller, Ph.D. continues as president and assumes chief...
Abeona Therapeutics Reports Fourth Quarter 2017 Financial Results and Business Highlights
March 16, 2018 17:10 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, March 16, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and...
Abeona Therapeutics Receives FDA Rare Pediatric Disease Designation for ABO-202 Gene Therapy Program in CLN1 Disease
March 15, 2018 08:45 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, March 15, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...
Abeona Therapeutics Announces Upcoming Conference Participation
February 21, 2018 08:45 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...
Abeona Therapeutics Receives FDA Orphan Drug Designation for ABO-202 Gene Therapy Program in Infantile Batten Disease
February 12, 2018 08:45 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...
Abeona Therapeutics Reports Top-Line Data from Phase 1/2 Gene Therapy Trial in MPS IIIA
February 08, 2018 14:00 ET
|
Abeona Therapeutics Inc.
ABO-102 results presented at WORLDSymposium for Lysosomal Diseases show significant time- and dose-dependent reduction of underlying disease pathology, including decreased CSF and urine GAGs (HS...
Abeona Therapeutics Reports on Initial Safety and Biopotency Signals in MPS IIIB Gene Therapy Clinical Trial
February 07, 2018 08:45 ET
|
Abeona Therapeutics Inc.
First-in-man AAV9-based gene therapy delivered by single intravenous injection targeting central nervous system and peripheral manifestations of MPS IIIB.ABO-101 is well tolerated and demonstrates...